drugset / Trial / NCT00853658

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

NCT00853658

Phase 3 Completed 7064 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.

Timeline

Start
2009-03
Primary completion
2015-10
Completion
2015-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg Oral
Subject Enalapril Other / unclassified 5 mg Oral
Subject Enalapril Other / unclassified 10 mg Oral

Indications